| Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 294.00 k | 294.00 k | 294.00 k | 294.00 k | 294.00 k | 294.00 k |
| Cash burn (monthly) | 76.67 k | 462.42 k | 1.05 mm | 2.48 mm | 324.00 k | 1.11 mm |
| Cash used (since last report) | 615.38 k | 3.71 mm | 8.40 mm | 19.94 mm | 2.60 mm | 8.88 mm |
| Cash remaining | -321.38 k | -3.42 mm | -8.10 mm | -19.64 mm | -2.31 mm | -8.58 mm |
| Runway (months of cash) | -4.2 | -7.4 | -7.7 | -7.9 | -7.1 | -7.8 |
| 13F holders | Current |
|---|---|
| Total holders | 12 |
| Opened positions | 1 |
| Closed positions | 12 |
| Increased positions | 1 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 79.51 mm |
| Total shares | 3.65 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| LGND Ligand Pharmaceuticals | 2.22 mm | $3.51 mm |
| Lind Global Fund II | 1.41 mm | $1.50 mm |
| Modera Wealth Management | 10.81 k | $40.57 mm |
| UBS UBS | 8.48 k | $31.83 mm |
| BlackRock | 354.00 | $1.33 mm |
| Tower Research Capital | 95.00 | $357.00 k |
| Carmichael Hill & Associates | 62.00 | $233.00 k |
| JPM JPMorgan Chase & Co. | 31.00 | $116.00 k |
| Crewe Advisors | 7.00 | $27.00 k |
| Vermillion & White Wealth Management | 7.00 | $26.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 29 Feb 24 | Michael Joseph Golembiewski | Common Stock | Grant | Acquire A | No | No | 1.097 | 417 | 457.45 | 86,869 |
| 12 Jan 24 | Mehra Raj | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 70,383 | 99.24 k | 70,383 |
| 12 Jan 24 | Michael Joseph Golembiewski | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 24,537 | 34.60 k | 24,537 |
| 4 Jan 24 | Lian Brian | Stock Option Common Stock | Grant | Acquire A | No | No | 1.33 | 1,666 | 2.22 k | 1,666 |
| 4 Jan 24 | Pascoe Richard W | Stock Option Common Stock | Grant | Acquire A | No | No | 1.33 | 1,666 | 2.22 k | 1,666 |
